Through the Mayo Nephrology Collaborative Group, doctors and scientists at Mayo Clinic and other medical centers collaborate to test new therapies and treatment strategies to increase the success rates of remission and enhance patient care.

Rituximab (Rituxan), a monoclonal antibody against B cells that has been used in a number of autoimmune conditions, is being studied at Mayo Clinic for the treatment of IgA nephropathy.

Publications

See a list of publications by Mayo doctors on IgA nephropathy on PubMed, a service of the National Library of Medicine.

Apr. 19, 2013